[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573066":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":20,"locations":30,"responsibleParty":48,"collaborators":10,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":10,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Vanderbilt University Medical Center","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Control",null,"Controls who meet the same inclusion\u002Fexclusion criteria, except they do not have preeclampsia and do not have pre-existing diabetes or chronic hypertension.",{"label":13,"type":10,"description":14,"interventionNames":10},"PreE Px","Preeclamptic participants who meet the inclusion\u002Fexclusion criteria",[16],{"name":17,"affiliation":18,"role":19},"Kathryn Lindley, MD, FACC","VUMC","PRINCIPAL_INVESTIGATOR",[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Olivia H Patridge, BS","CONTACT","615-875-2942","olivia.h.patridge@vumc.org",{"name":27,"role":23,"phone":28,"phoneExt":10,"email":29},"Cassandra F Reynolds, BS, CCRC","615-875-9854","cassandra.f.reynolds@vumc.org",[31],{"facility":5,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Nashville","Tennessee","37203","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-86.78444,36.16589,{"lat":42,"lon":41},[45],{"name":17,"role":23,"phone":46,"phoneExt":10,"email":47},"615-322-1710","kathryn.lindley@vumc.org",{"type":19,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Kathryn Lindley","Dr. Kathryn Lindley, MD, FACC","100573066","exercise-testing-after-preeclampsia-100573066",false,"NCT06741436","Exercise Testing After Preeclampsia","Identification of Early HFpEF After Preeclampsia by Exercise Stress Testing","Inclusion Criteria:\n\n1. Women age \\> 18 years\n2. Give birth at VUMC\n3. Have a diagnosis of PreE based on accepted American College of Obstetricians and Gynecologists criteria\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years old\n2. Unable to provide informed consent\n3. Does not speak English\n4. Active COVID-19 infection\n5. Residual symptoms related to prior COVID-19 infection\n6. HIV infection\n7. Hepatitis B or C infection\n8. Pulmonary arterial hypertension\n9. Sickle cell disease\n10. Pulmonary embolism\n11. Pre-existing cardiomyopathy\n12. Coronary artery disease\n13. Active substance abuse (other than tobacco or marijuana)\n14. Unable to attend postpartum visits\n\nControls\n\n1\\. Enrolling controls who meet the same inclusion\u002Fexclusion criteria, except they do not have preeclampsia and do not have pre-existing diabetes or chronic hypertension.",true,"FEMALE","18 Years",{"count":62,"type":63},500,"ESTIMATED","OBSERVATIONAL","Though cardiovascular disease (CVD) is the leading cause of mortality in women, traditional epidemiology in this area has focused on later life, when cardiometabolic risk has already exacted a cumulative toll on the vascular system. Recent data from the investigators and others has highlighted pregnancy as a unique, early moment of cardiovascular stress in young women that may \"unmask\" CVD propensity. It is unclear if PreE simply represents a \"failed stress test\" or directly contributes to the pathophysiology of future CVD. While mechanistic studies have largely been the purview of model-based studies, endothelial dysfunction has emerged as central to the pathogenesis of both PreE and peripartum cardiac dysfunction. Indeed, biomarkers of endothelial dysfunction and angiogenic imbalance during pregnancy have been shown to remain elevated at least 6 months post-partum. Moreover, peri-partum endothelial dysfunction can persist for years post-delivery and remains a significant risk factor for CVD (even after adjustment for other traditional risk factors). While these findings suggest that PreE-associated endothelial dysfunction and inflammation may contribute to early myocardial dysfunction that presages HF risk decades before its onset, the modifiable epidemiology of PreE-associated LVDD, including potential mechanisms of risk, remains unclear, limited by lack of precision molecular phenotypes accessible in a large number of American women across race. Ultimately, understanding the epidemiology and pathobiology of PreE-associated myocardial dysfunction affords a unique opportunity to identify women at risk with a longer lead-time for risk factor modification to interrupt CVD.\n\nThe investigators hypothesize that persistent structural-functional myocardial alterations after PreE are linked to pre- and post-gravid cardiometabolic risk factors (SA1), functional and hemodynamic impairment (SA2) and select pathways of vascular and inflammatory stress relevant to HF risk (SA3). Despite extensive study on the role of inflammation\u002Fischemia in PreE, there have been no large studies connecting these phenotypes with early PP functional response and biochemical alterations, a key barrier to designing studies for improving CVD\u002FHF in women.\n\nSA1: To identify pregnancy-specific clinical factors related to postpartum HFpEF phenotypes Clinical Implication: Improve identification of women at highest risk for developing post-PreE LV diastolic dysfunction (a harbinger of HFpEF).\n\nSA2: To define functional and hemodynamic signatures of early HFpEF due to preeclampsia\n\nClinical Implication: Identify women at highest risk for developing early HFpEF.\n\nSA3: To identify shared pathophysiologic mechanistic pathways for PreE-associated HFpEF Clinical Implication: Identify targetable pathways for post-PreE cardiac dysfunction that may prevent\u002F delay HFpEF development.",[67,68,69],"Preeclampsia","Heart Failure Preserved Ejection Fraction","Hypertension",[71,72,73],"CPET","Placental vascular dysfunction","echo","2026-04-13",{"date":76,"type":77},"2026-04-14","ACTUAL",{"date":79,"type":77},"2025-02-18",{"date":81,"type":63},"2029-06-30",{"name":5,"class":6},1]